Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review

Immune checkpoint inhibitors (ICIs) have been approved for patients with advanced non-small-cell lung cancer (NSCLC), regardless of histology. However, histologic subtypes of NSCLC may influence treatment outcomes of ICIs. We conducted this meta-analysis to investigate if there is difference in surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bum Jun, Kim, Jung Han, Kim, Hyeong Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584287/
https://www.ncbi.nlm.nih.gov/pubmed/28881686
http://dx.doi.org/10.18632/oncotarget.17213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584287/
https://www.ncbi.nlm.nih.gov/pubmed/28881686
http://dx.doi.org/10.18632/oncotarget.17213

Ejemplares similares